Unlock Exclusive Discounts & Flash Sales! Click Here to Join the Deals on Every Wednesday!

In Vivo Pharmacodynamic Evaluation of Oxalic Acid-Induced Chronic Kidney Disease (CKD) Model (CAT#: STEM-AE-0669-LGZ)

Introduction

Metabolic diseases are diseases caused by the accumulation or deficiency of certain metabolic substances such as sugars, fats, proteins (amino acids), purines, pyrimidines, and copper when biochemical processes in the body are disrupted. Symptoms vary in severity and diagnosis depends on clinical manifestations and blood, urine and other biochemical tests. There is no effective cure, the main is to eliminate the cause and symptomatic treatment. The prognosis depends on the etiology, severity of symptoms and treatment effect.




Principle

Hyperoxaluria results from either inherited disorders of glyoxylate metabolism leading to hepatic oxalate overproduction (primary hyperoxaluria), or increased intestinal oxalate absorption (secondary hyperoxaluria). Hyperoxaluria may lead to urinary supersaturation of calcium oxalate and crystal formation, contributing to urolithiasis and deposition of calcium oxalate crystals in the kidney parenchyma, leading to oxalate nephropathy.

Applications

Metabolic Disease

Procedure

1. Disease model construction.
2. Mice dosing.
3. Efficacy monitoring.
4. Biochemical detection of tissue samples.

Materials

• Sample Type: liquid or powder
Advertisement